From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?

Read also

• Datamonitor Healthcare: data analysis and insight

  mHealth and Research in Oncology

  The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit. 

  Read Blog

• Datamonitor Healthcare: data analysis and insight, Biomedtra...

  Gene therapy manufacturers

  Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

  Read Blog

• Biomedtracker: see the drug development process through anal...

  Deconstructing the KRAS+ market opportunity

  By Daniel Chancellor

  With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target

  Topics BioPharmaceutical Drug Review

  Read Blog